Liquid Dosage

Oncology

As a result of growing competition and more stringent regulatory requirements for end-user safety, improving the convenience and ease of administration of parenteral therapeutics is becoming a common strategy for biotechnology and pharmaceutical companies. Manufacturers wishing to gain market share and provide high quality products for healthcare professionals and cancer patients alike are increasingly investing in the development and delivery of liquid dosage forms, freeze-dried products and injectables.

Pharmaceutical Development

GEA is known all over the world for its individual and tailor-made process plant for the manufacture of free-flowing pharmaceutical and biotechnology products. Complete plant, modular equipment, process units and skids can be assembled, tested and qualified in our own production facilities. We perform tests and trial runs with appropriate media to demonstrate the functionality of all components and equipment before the plant is delivered.

In collaboration and partnership with our customers, we aim to develop and deliver high-performance plant and economic process systems that comply with the highest operational safety and environmental standards; we want our customers to use our groundbreaking solutions to manufacture even better products in the future.

GEA can supply a specialized, contained and fully integrated system when no standard off-the-shelf one exists, particularly for toxic or highly potent drugs such as cytostatics or echo contrast media. With our innovative ideas and fresh approaches, together with your project team, we will find a solution that’s tailored to your needs — from basic engineering to fabrication and qualification.  

Downloads

GEA Insights

Human hands brought together to form a circle

Gesellschaftliches Engagement: Gemeinsam Gutes bewirken

Zur Unterstützung des gesellschaftlichen Engagements bietet GEA seinen Mitarbeitern einen Tag bezahlten Urlaub pro Jahr.

How a digital rotary parlor supports sustainable dairy farming

How do you lead a dairy farm into the next generation while ensuring a sustainable future and animal welfare while managing increasing complexity? This is a question almost every dairy farmer around the world must consider. The...

GEA misison 30 logo

Zukunft gestalten: GEA-CEO Stefan Klebert zur Mission 30

Nachdem GEA die Ziele der Mission 26 zwei Jahre früher erreicht hat, setzt sich das Unternehmen ambitionierte Ziele, um in den kommenden Jahren profitabel zu wachsen.

Erhalten Sie Nachrichten von GEA

Informieren Sie sich über GEA Innovationen und Erfolgsgeschichten, indem Sie die News von GEA abonnieren.

Haben Sie Fragen?

Wir helfen Ihnen gern weiter! Mit nur wenigen Angaben können wir Ihre Anfrage beantworten.

© GEA Group Aktiengesellschaft 2024

Cookie settings